Eliphos
Loading...Eliphos Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Patients with end stage renal failure may develop hypercalcemia when given calcium with meals. No other calcium supplements should be given concurrently with ELIPHOS® .
Progressive hypercalcemia due to overdose of ELIPHOS® may be severe as to require emergency measures. Chronic hypercalcemia may lead to vascular calcification, and other soft-tissue calcification. The serum calcium level should be monitored twice weekly during the early dose adjustment period.
The serum calcium times phosphate (CaXP) product should not be allowed to exceed 66. Radiographic evaluation of suspect anatomical region may be helpful in early detection of soft-tissue calcification.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
ELIPHOS® is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption.
History
There is currently no drug history available for this drug.
Other Information
Each white, round tablet (stamped “CYP910”) contains 667 mg calcium acetate, USP (anhydrous; Ca(CH3COO)2; MW=158.17 grams) equal to 169 mg (8.45 mEq) calcium, polyethylene glycol 8000 NF; sodium lauryl sulfate, NF; and crospovidone, NF. ELIPHOS® (Calcium Acetate, USP) are administered orally for the control of hyperphosphatemia in end stage renal failure.
Sources
Eliphos Manufacturers
-
Kaiser Foundation Hospitals
![Eliphos (Calcium Acetate) Tablet [Kaiser Foundation Hospitals]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Eliphos | Kaiser Foundation Hospitals
The recommended initial dose of ELIPHOS® for the adult dialysis patient is 2 tablets with each meal. The dosage may be increased gradually to bring the serum phosphate value below 6 mg/dl, as long as hypercalcemia does not develop. Most patients require 3-4 tablets with each meal.
-
Hawthorn Pharmaceutical, Inc.
Eliphos | Hawthorn Pharmaceutical, Inc.
The recommended initial dose of ELIPHOS® for the adult dialysis patient is 2 tablets with each meal. Increase the dose gradually to lower serum phosphorus levels to the target range, as long as hypercalcemia does not develop. Most patients require 3-4 tablets with each meal.
-
Carilion Materials Management
Eliphos | Carilion Materials Management
The recommended initial dose of ELIPHOS(R) for the adult dialysis patient is 2 tablets with each meal. The dosage may be increased gradually to bring the serum phosphate value below 6 mg/dl, as long as hypercalcemia does not develop. Most patients require 3–4 tablets with each meal. Dosage and Administration:
![Eliphos (Calcium Acetate) Tablet [Hawthorn Pharmaceutical, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7f58ea4d-e5cc-4898-879f-ffba6207b098&name=eliphos-02.jpg)
![Eliphos (Calcium Acetate) Tablet [Carilion Materials Management]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9fc1ada4-9ef4-48e9-8203-32aa857d0429&name=68151-5204.jpg)
Login To Your Free Account